Skip to main content

Organon & Co Value Stock - Dividend - Research Selection

Organon & company

ISIN: US68622V1061 , WKN: A3CPKP

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

2024-12-19
JERSEY CITY, N.J., December 19, 2024--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

2024-12-17
Organon (OGN) announced that the U.S. Food and Drug Administration or FDA has approved VTAMA or tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis AD in adults and pediatric patients 2 years of age and older.Organon received the FDA approval prior to its extended target action date PDUFA of March 12. “With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there

Organon - FDA Approves VTAMA cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

2024-12-17
JERSEY CITY - Organon , a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration has approved VTAMA...

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

2024-12-16
JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a first-in-class therapy with new FDA approval for atopic dermatitis in adults and children aged 2 and older.

Harbor Mid Cap Value Fund Q3 2024 Commentary

2024-12-05
During the third quarter, the Harbor Mid Cap Value Fund (Institutional Class) slightly lagged its benchmark, the Russell Midcap Value Index.

Roivant Sciences: A Biotech Growth Play With Major Ambitions

2024-12-04
Roivant Sciences' diversified late-stage pipeline and robust financials promise significant growth potential. Read why I maintain my buy rating on ROIV stock.

AbbVie: Upgrading To 'Strong Buy' After Pullback

2024-11-22
AbbVie’s high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.

Organon: 7% Yield, 4x P/E, Big Upside Potential

2024-11-14
Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative acquisitions. Explore more details here.

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)

2024-11-13
Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth. Check out why I upgraded OGN stock to buy from hold.

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

2024-11-08
Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found some...